secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kalaris Therapeutics, Inc. (KLRS)
CIK:        0001754068
Form:       8-K
Filed at:   2026-07-17T11:05:41+00:00
Accession:  0001193125-26-306737
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kalaris reports positive expanded Phase 1a data for TH103 in nAMD; 29% no retreatment in 6 months
--------------------------------------------------------------------------------

- Expanded Phase 1a SAD dataset: 17 treatment-naïve + 3 treatment-experienced patients; all 20 completed 6-month follow-up.
- After single TH103 injection, 41% of treatment-naïve patients retreatment at ≥4 months, 29% no anti-VEGF treatment in 6 months.
- Mean 9.2-letter BCVA improvement, 118µm CST reduction, 93% reduction in intraretinal fluid at one month.
- TH103 plasma Cmax 27- to 53-fold lower vs leading anti-VEGF agents on molar equivalence basis.
- No IOI at 2.5 mg with improved manufacturing; Phase 1b/2 enrolling, initial data expected 1H 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1754068/000119312526306737/0001193125-26-306737-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1754068/000119312526306737/d125006d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-306737

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer